Keymed Biosciences, announced the National Medical Products Administration of China has recently approved the supplemental New Drug Application of Stapokibart, for the treatment of chronic rhinosinusitis with nasal polyposis.
HealthTech Insights: How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of patients with chronic rhinosinusitis with nasal polyposis. The study results showed that the data from the phase III clinical trial was positive. Compared to the placebo, Stapokibart significantly reduced nasal polyps (NPS improvement of 2.3 from baseline) and alleviated nasal congestion (NCS improvement of 0.7 from baseline) after 24 weeks. The differences were highly statistically significant (P<0.0001). Additionally, it effectively relieved rhinosinusitis, restored sense of smell, improved nasal symptoms, and enhanced quality of life. It also demonstrated a favorable safety profile.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
